<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543607</url>
  </required_header>
  <id_info>
    <org_study_id>11-405</org_study_id>
    <nct_id>NCT01543607</nct_id>
  </id_info>
  <brief_title>Endoscopic Therapy of Malignant Bile Duct Strictures</brief_title>
  <official_title>Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with malignant bile duct stenosis have poor prognosis and most of the patients are
      not good candidate for surgery at the time of diagnosis. Placement of the stent is the
      palliative care for these patients. However over 50% of the stents get blocked within 6-8
      months. Use of the radiofrequency ablation before the stent placement may improve stent
      patency. Heat will be applied to the bile duct in order to open the blockage and prevent the
      re-growth of tissue into the stent. The investigators are looking to see how safe and
      feasible RFA (Radiofrequency ablation) catheter is in patient with malignant bile duct
      stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of medical care subjects will be undergoing an endoscopic procedure (ERCP) in order
      to evaluate and stent a bile duct blockage. During the ECRP and just prior to the stent
      placement subjects will undergo the placement of a radiofrequency ablation catheter into the
      bile duct blockage. Heat will be applied to the bile duct in order to open the blockage and
      prevent the re-growth of tissue into the stent; after the radiofrequency ablation, stent will
      be placed. Three days after the procedure subjects will receive a phone call from the
      research coordinator to check any adverse or unwanted effects of the treatment. The study
      procedure (radiofrequency ablation) takes place over 10 minutes during ERCP. The subjects
      will undergo routine follow up for their medical problems. No follow up visits are required
      as part of the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of Bile Leak After RFA Procedure</measure>
    <time_frame>2 years</time_frame>
    <description>Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility: Ease of the Radiofrequency Ablation Catheter Placement</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change From Baseline in Bile Duct Diameter.</measure>
    <time_frame>2 years</time_frame>
    <description>Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure. This will be measure as percentage change in improvement of the stricture.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Obstruction of Biliary Tree</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation catheter (Habib EndoHBP)</intervention_name>
    <description>Catheter placement into bile duct</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Habib EndoHBP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented malignant biliary obstruction requiring ERCP guided stenting

        Exclusion Criteria:

          -  Coagulopathy (INR &gt; 2.0 or PTT &gt; 100 sec or platelet count &lt; 50,000)

          -  Evidence of high-grade symptomatic duodenal obstruction

          -  Poor performance status

          -  Active suppurative cholangitis

          -  Complex stenoses will not be eligible for the trial

          -  Patients without access to duodenum or ampulla are not candidates for ERCP and
             stenting

          -  Candidates for a Whipple resection

          -  Patients who do not speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William R Brugge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://crnet.mgh.harvard.edu/trials.aspx?tId=4702</url>
    <description>Study information</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>William R. Brugge, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bile duct</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Bile duct stenosis</keyword>
  <keyword>Malignant bile duct obstruction</keyword>
  <keyword>Malignant bile duct stricture</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>RFA</keyword>
  <keyword>Endoscopic RFA catheter</keyword>
  <keyword>EndoHPB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Number of Bile Leak After RFA Procedure</title>
        <description>Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Bile Leak After RFA Procedure</title>
          <description>Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)</description>
          <units>bile leak</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility: Ease of the Radiofrequency Ablation Catheter Placement</title>
        <description>Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility: Ease of the Radiofrequency Ablation Catheter Placement</title>
          <description>Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness: Change From Baseline in Bile Duct Diameter.</title>
        <description>Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure. This will be measure as percentage change in improvement of the stricture.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness: Change From Baseline in Bile Duct Diameter.</title>
          <description>Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure. This will be measure as percentage change in improvement of the stricture.</description>
          <units>percentage of improvement:</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Radiofrequency ablation catheter
Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William R. Brugge</name_or_title>
      <organization>Mass. General Hospital</organization>
      <phone>617-724-0578</phone>
      <email>wbrugge@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

